Truist keeps the firm’s Buy rating and a $1,281 price target on Eli Lilly (LLY). The company’s retatrutide Phase 3 clinical trial data in obesity announced this morning, where patients on retatrutide high dose of 12 mg saw 28.3% weight loss at 80 weeks and 30.3% at 104 weeks, represent a new benchmark for anti-obesity medications and will support retatrutide approval and use in patients that are not adequately served with existing incretin options, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly’s retatrutide Triumph-1 study a ‘clean win’, says RBC Capital
- Eli Lilly reports retatrutide meets primary endpoint in TRIUMPH-1 study
- Eli Lilly Raises $8.9 Billion in Debt Offering
- Eli Lilly (LLY) Acquires Engage Biologics for $202 Million
- Eli Lilly acquires Engage Biologics for up to $202M in cash